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C
ancer is caused by alterations in oncogenes, tumor-suppressor 
genes, and microRNA genes. These alterations are usually somatic events, 
although germ-line mutations can predispose a person to heritable or famil-
ial cancer. A single genetic change is rarely sufficient for the development of a 
malignant tumor. Most evidence points to a multistep process of sequential altera-
tions in several, often many, oncogenes, tumor-suppressor genes, or microRNA 
genes in cancer cells.
Tumors often possess cytogenetically different clones that arise from the initial 
transformed cell through secondary or tertiary genetic alterations. This heteroge-
neity contributes to differences in clinical behavior and responses to treatment of 
tumors of the same diagnostic type. Apart from the initial clone and subclones, 
tumors can also contain progenitor cancer cells, all of which constitute a spec-
trum of cells with different genetic alterations and states of differentiation. These 
populations can differ in sensitivity to chemotherapy, radiotherapy, and other 
treatments, making clinical management difficult. For these reasons, the initiat-
ing steps in the development of cancer are of considerable clinical importance and 
are a priority in the development of rational cancer treatment.
An example of this concept is chronic myelogenous leukemia, which is initi-
ated by a reciprocal t(9;22) chromosomal translocation that fuses the ABL proto-
oncogene to the BCR gene.1,2 The fusion gene encodes an oncogenic ABL fusion 
protein with enhanced tyrosine kinase activity. All leukemic cells carry this chromo-
somal alteration, which is why inhibition of the excessive tyrosine kinase activity 
of the fusion protein by imatinib induces complete remission in most patients3,4; 
when relapse occurs, the leukemic cells usually carry mutations in ABL that render 
them resistant to the drug.5
Evidence of Somatic Genetic Change
The first evidence that cancer arises from somatic genetic alterations came from 
studies of Burkitt’s lymphoma, in which one of three different translocations juxta-
poses an oncogene, MYC, on chromosome 8q24 to one of the loci for immunoglobulin 
genes. Chromosomes 14q, 22q, and 2p — the translocation partners — each carries 
enhancer elements in the immunoglobulin loci, thereby activating the juxtaposed 
MYC oncogene (see Fig. 1 in the Supplementary Appendix, available with the full text 
of this article at www.nejm.org).6-11 Since every malignant lymphocyte carries the 
MYC translocation, deregulation of the MYC oncogene is probably the initiating event.
Second, transfection experiments have shown that mouse fibroblasts, when trans-
fected in vitro with DNA from human cancer cells, acquire some of the properties 
of malignant cells (i.e., transformation). The transforming activity of the DNA was 
traced to a human homologue of the retroviral RAS oncogene. This oncogene bears 
mutations that activate the transforming property of the RAS oncogenic protein.12,13
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Third, the cloning and characterization of the 
chromosomal breakpoints that are characteristic 
of follicular lymphomas and some diffuse large 
B-cell lymphomas14 have shown a juxtaposition 
of the BCL2 oncogene to enhancer elements in 
the immunoglobulin heavy-chain locus, resulting 
in deregulation of BCL214,15 (see Fig. 2 in the 
Supplementary Appendix).
Fourth, in transgenic mice that carry an acti-
vated oncogene from a human tumor, cancers 
develop that resemble the human tumor.16,17 That 
these cancers appear only after a latent period 
suggests that alterations in other genes must 
occur before progression to frank neoplasia can 
occur  —  activation  of  a  particular  oncogene 
seems to be necessary but not sufficient for the 
development of overt cancer.
Functional Properties  
of Oncogenes
Historically, transformation events in cancer have 
been defined as initiation events (contributing to 
the early stages of neoplastic transition) or pro-
gression events (referring to subsequent trans-
formative processes). Oncogenes encode proteins 
that control cell proliferation, apoptosis, or both. 
They can be activated by structural alterations 
resulting from mutation or gene fusion,18 by jux-
taposition to enhancer elements,19 or by amplifi-
cation. Translocations and mutations can occur 
as initiating events20 or during tumor progression, 
whereas amplification usually occurs during pro-
gression. (Table 1 in the Supplementary Appen-
dix lists oncogenes in tumors of different spe-
cies, the methods used to identify them, their 
mechanisms of activation, and the functions of 
their encoded products; Table 2 in the Supple-
mentary Appendix lists the molecularly charac-
terized chromosomal rearrangements in human 
cancers.) The products of oncogenes can be clas-
sified into six broad groups: transcription factors, 
chromatin remodelers, growth factors, growth 
factor receptors, signal transducers, and apopto-
sis regulators.
Products of Oncogenes
Transcription Factors
Transcription factors are often members of mul-
tigene families that share common structural 
domains. To act, many transcription factors re-
quire interaction with other proteins. In some tu-
mors, for example, the Fos transcription protein 
dimerizes with the Jun transcription factor to 
form the AP1 transcription factor, and this com-
plex increases the expression of several genes that 
control cell division.21,22
Chromosomal  translocations  often  activate 
transcription-factor genes in lymphoid cancers23 
and sometimes do so in solid tumors (e.g., pros-
tate cancer24; see Table 2 in the Supplementary 
Appendix). In certain sarcomas, chromosomal 
translocations that result in fused proteins occur 
consistently; in Ewing’s sarcoma, for example, 
the EWS gene is fused with one of a number of 
partner genes, resulting in aberrant transcrip-
tional activity of the fused proteins (see Table 2 in 
the Supplementary Appendix). The EWS protein 
is an RNA-binding molecule with a domain that, 
when fused to a heterologous DNA-binding do-
main, can greatly stimulate gene transcription. 
Prostate carcinomas carry translocations of the 
TMPR552 gene that fuse with and activate ERG1 
or ETV1. These genes are members of the ETS 
family of transcription regulators, which can ac-
tivate or repress genes involved in cellular prolif-
eration, differentiation, and apoptosis. The fusion 
of TMPR552, which has androgen-responsive pro-
moter elements, with an ETS-related gene creates 
a fusion protein that increases proliferation and 
inhibits apoptosis of cells in the prostate gland, 
thereby facilitating their transformation into can-
cer cells.24
Chromatin Remodelers
Modifications in the degree of compaction of 
chromatin play a critical role in the control of gene 
expression, replication, and repair and of chromo-
some segregation. Two kinds of enzymes remodel 
chromatin: ATP-dependent enzymes25 that move 
the positions of nucleosomes, the repeating sub-
units of the histones in chromatin around which 
DNA winds, and enzymes that modify the N-ter-
minal tails of histones.26 The pattern of histone 
modification constitutes an epigenetic code that 
determines the interaction between nucleosomes 
and chromatin-associated proteins.27 These inter-
actions, in turn, determine the structure of chro-
matin and its transcriptional capacity.
In acute lymphocytic leukemia and acute my-
elogenous leukemia, the ALL1 (also named MLL) 
gene can fuse with 1 of more than 50 genes. 
ALL1 is part of a very large, stable multiprotein 
complex. Most of the proteins in the complex are 
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components of transcription complexes28; others 
are involved in histone methylation and RNA 
processing. The entire complex remodels, acety-
lates, deacetylates, and methylates nucleosomes 
and free histones.28 The fusion of ALL1 with 1 of 
more than 50 proteins results in the formation 
of the chimeric proteins that underlie acute lym-
phoblastic leukemia and acute myelogenous leu-
kemia. ALL1 (MLL) fusion proteins deregulate 
homeobox genes (which encode transcriptions 
factors), the EPHA7 gene (which encodes a recep-
tor tyrosine kinase), and microRNA genes such as 
miR191.
Growth Factors
Constitutive activation of a growth factor gene can 
contribute to malignant transformation. Platelet-
derived growth factor (PDGF) consists of   and 
  chains and is released from platelets during 
coagulation.29 It can induce the proliferation of 
various cell types and stimulate fibroblasts to par-
ticipate in wound healing. The sis oncogene of 
simian sarcoma virus is structurally similar to 
the gene for the   chain of PDGF.29 Overexpres-
sion of PDGF induces the in vitro transformation 
of fibroblasts containing PDGF receptors; it does 
not influence fibroblasts lacking these receptors. 
This  autocrine  loop  entails  overexpression  of 
PDGF- , the expression of the PDGF-  receptor, 
and unregulated cell growth. An antibody against 
PDGF- , an antibody against its receptor, or small 
molecules that block the receptor inhibit growth 
of the transformed fibroblasts.
The WNT family of secreted glycoproteins 
inhibits phosphorylation of  -catenin, which is 
involved in cell–cell adhesion and the activation 
of several signal-transduction pathways30 (Fig. 
1).  The  APC  protein  controls  the  activity  of 
 -catenin. In familial adenomatous polyposis, 
inactivating mutations of APC block the degrada-
tion of  -catenin by inhibiting its phosphoryla-
tion. As a result, free  -catenin in the cytoplasm 
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Figure 1. Dual Functions of  -Catenin in Cell Adhesion and Transcription.
 -Catenin is in a destructive cytoplasmic complex composed of activated protein C (APC), axin, glycogen synthase kinase 3 beta (GSK3 ), 
and casein kinase (CK1). CK1 and GSK3  induce serine–threonine phosphorylation of the N-terminal of  -catenin. Binding of Wnt 
  ligands to the frizzled (Fz), LRP5, and LRP6 receptors inhibits the degradation of this complex and leads to nuclear accumulation of  
 -catenin. Phosphorylation (P) of tyrosine 142 of  -catenin leads it to interact with BCL9-2 and to migrate to the nucleus, where the  
 -catenin–BCL9-2 complex binds LEF and TCF to induce the expression of target genes. Phosphorylation of tyrosine Y654 of  -catenin 
results in the disassociation of E-cadherin and  -catenin, causing loss of cell–cell adhesion and increased cell motility.6-11
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translocates to the nucleus, where it activates 
genes involved in cell proliferation and invasion 
(Fig. 1).
Growth Factor Receptors
Growth factor receptors are altered in many can-
cers (Fig. 2).31 In many tumors, a deletion of the 
ligand-binding domain of epidermal growth fac-
tor receptor (EGFR), a transmembrane protein 
with tyrosine kinase activity, causes constitutive 
activation of the receptor in the absence of ligand 
binding.32 The activated receptor phosphorylates 
tyrosines in the intracellular domain of the recep-
tor, providing interaction sites for cytoplasmic 
proteins containing the SRC homology domain 
and other binding domains. These interactions de-
regulate signaling in several pathways. Activat-
ing mutations occur in three other members of 
the EGFR family — ERBB2, ERBB3, and ERBB4 
— and within the kinase domains of the HER2/neu 
and KIT signaling receptors. Such mutations oc-
cur in lung and breast cancer and gastrointestinal 
stromal tumors. Two classes of clinically active 
anti-EGFR agents have been developed: a mono-
clonal antibody against the extracellular domain 
of the receptor (cetuximab) and competitive in-
hibitors of the tyrosine kinase activity of the re-
ceptor (e.g., erlotinib and gefitinib).
Vascular endothelial growth factor (VEGF) reg-
ulates hypoxia-dependent control of gene tran-
scription (Fig. 3). The activity of VEGF is medi-
ated by three receptor tyrosine kinases: VEGFR1 
(FLT1), VEGFR2 (FLK1-KDR), and VEGFR3 (FLT4). 
VEGF stimulates angiogenesis in a variety of can-
cers, and inhibitors of VEGF and of the VEGFRs 
have been developed. Bevacizumab is a mono-
clonal anti-VEGF antibody, and SU5412, a small 
molecule, binds the receptor tyrosine kinases of 
VEGFR1 and VEGFR2 as well as the kinases of the 
PDGF receptor and KIT. In addition to inhibiting 
the ABL kinase, imatinib also inhibits the PDGF 
and KIT receptor kinases. Gastrointestinal stro-
mal tumors that carry activating mutations of 
KIT  33,34 respond to imatinib or other inhibitors 
of these receptor kinases.
Signal Transducers
Binding of receptor tyrosine kinases to the ap-
propriate ligand causes reorganization of the re-
ceptors and autophosphorylation of tyrosines in 
the intracellular portion of the molecules35 (Fig. 
2). Autophosphorylation enhances the kinase ac-
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Figure 3. Role of VEGF–VEGFR Interaction in Angiogenesis.
Several pathways are activated by the interaction of vascular endothelial 
growth factor (VEGF) and VEGF receptors (VEGFR). FAK denotes fatal ad-
hesion kinase, Flk fetal liver kinase, IP3 inositol triphosphate, KDR kinase-
insert domain–containing receptor, MAPK mitogen-activated protein kinase, 
PI3K phosphoinositol 3-kinase, PKB protein kinase B, and PLC phospholi-
pase C.
COLOR  FIGURE
AUTHOR PLEASE NOTE:
Figure has been redrawn and type has been reset
Please check carefully
1/08/08 Draft 3
2
SBL
Croce Author
Fig #
Title
ME
DE
Artist
Issue date
EGF
receptor
PDGF
receptor
NGF
receptor
FGF
receptor
VEGF
receptor
Cytoplasmic tyrosine kinase domain
Extracellular domain
Cell
membrane
Cysteine-rich
domain
SS SS SS
Cytosol
IGF-1
receptor
Ig-like
domain
Figure 2. Examples of Receptor Tyrosine Kinases.
The epidermal growth factor (EGF), insulin-like growth factor 1 (IGF-1), 
platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) 
  receptors have been found to be involved in a variety of human cancers.  
NGF denotes nerve growth factor, SS disulfide bonds, and VEGF vascular 
endothelial growth factor.
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tivity of the receptor or promotes the interaction 
of the  receptor  with  domains  of  cytoplasmic 
proteins (e.g., the SRC homology 2 domain) that 
are effectors and regulators of intracellular sig-
naling.36 In humans, there are approximately 120 
SRC homology 2 domains in 100 different pro-
teins that mediate responses to signals initiated 
by phosphorylated tyrosines. Some of these pro-
teins  share  domains  with  enzymatic  activity, 
whereas others link activated receptors to down-
stream targets.
Many oncogenes encode members of signal-
transduction pathways. They fall into two main 
groups: nonreceptor protein kinases and guano-
sine-triphosphate–binding proteins.37,38 The non-
receptor protein kinases are of two types: tyro-
sine kinases (e.g., ABL, LCK, and SRC) and serine 
and threonine kinases (e.g., AKT, RAF1, MOS, 
and PIM1). Proteins involved in signal transduc-
tion become oncogenic if they bear activating 
mutations. An important example is PI3K and 
some of its downstream targets, such as AKT 
and SGK, which are critical to tyrosine kinase 
signaling and can be mutated in cancer cells.
Apoptosis Regulators
The BCL2 gene, which is involved in the initiation 
of almost all follicular lymphomas and some dif-
fuse large B-cell lymphomas (see Fig. 2 in the 
Supplementary Appendix),14,15 encodes a cytoplas-
mic protein39,40 that localizes to mitochondria 
and increases cell survival by inhibiting apopto-
sis.41 BCL2 is also important in chronic lympho-
cytic leukemia and lung cancer. The BCL2 family 
members  BCL-XL  and  BCL2  inhibit  apoptosis 
and are up-regulated in many cancers.
Two main pathways lead to apoptosis: the 
stress pathway and the death-receptor pathway 
(Fig. 4). The stress pathway is triggered by pro-
teins that contain the BCL2 homology 3 domain; 
this domain inactivates BCL2 and BCL-XL (which 
normally inhibit apoptosis) and thereby activates 
the  caspases  that  induce  apoptosis  (Fig.  4). 
Drugs that mimic the BCL2 homology 3 domain 
and can bind to BCL-XL or BCL2 (peptides or 
small organic molecules that bind in a groove of 
these proteins) are under development. This ap-
proach has attracted considerable attention be-
cause many tumors overexpress BCL2 or related 
proteins. The death-receptor pathway is activated 
by the binding of Fas ligand, TRAIL, and tumor 
necrosis factor  , to their corresponding (death) 
receptors on the cell surface. Activation of death 
receptors activates caspases that cause cell death 
(Fig. 4).
Oncogene Activation
Activation  of  oncogenes  by  chromosomal  re-
arrangements, mutations, and gene amplification 
confers a growth advantage or increased survival 
of cells carrying such alterations. All three mech-
anisms cause either an alteration in the oncogene 
structure or an increase in or deregulation of its 
expression.42
Chromosomal Rearrangements
Chromosome inversions and translocations are 
common cytogenetic abnormalities in cancer cells. 
In hematopoietic cancers and solid tumors, the 
translocations and inversions increase or deregu-
late transcription of the oncogene. In prostate 
cancer, gene fusion occurs between a gene that 
carries a promoter that is very active in the target 
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Figure 4. The Two Main Pathways to Programmed Cell Death, or Apoptosis.
The effectors of cell death are the downstream caspases, proteolytic en-
zymes activated by caspases 8 and 9, which are capable of clearing many  
of the cellular proteins causing cell death. FADD denotes Fas-associated 
death domain.
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cells, and another that carries the oncogenic ac-
tivity (e.g., ERG1).24 In cancers of B and T cells, 
the most common mechanism of activation by 
translocation resembles MYC deregulation, where-
as in myeloid cancers and soft-tissue sarcomas, 
gene fusion is more common (see Table 2 in the 
Supplementary Appendix).
Mutations
When an oncogene is activated by mutation, the 
structure of the encoded protein is changed in a 
way that enhances its transforming activity. Many 
types of mutation occur in oncogenes.43 Exam-
ples are the RAS oncogenes (KRAS, HRAS, and 
NRAS), which encode proteins with guanosine-
nucleotide–binding activity and intrinsic guano-
sine triphosphatase activity. When mutated in 
codon 12, 13, or 61, the RAS genes encode a 
protein that remains in the active state and con-
tinuously transduces signals by linking tyrosine 
kinases to downstream serine and threonine ki-
nases. These incessant signals induce continuous 
cell growth. Mutation of oncogenes in the RAS 
family has been associated with exposure to envi-
ronmental carcinogens. Mutations of KRAS are 
common in carcinomas of the lung, colon, and 
pancreas,43 whereas mutations of NRAS occur 
principally in acute myelogenous leukemia and 
the myelodysplastic syndrome.44
Activating point mutations of the BRAF gene 
occur in 59% of melanomas, 18% of colorectal 
cancers, 14% of hepatocellular carcinomas, and 
11% of gliomas.45 Most of the BRAF mutations 
change the valine residue at position 599 to glu-
tamic acid (V599E). This change occurs within 
the kinase domain of the BRAF protein, resulting 
in a constitutively active protein that uncontrol-
lably stimulates the MAP kinase cascade, thereby 
deregulating genes involved in cell proliferation, 
differentiation, and survival.45,46 In melanoma, 
BRAF mutations can precede neoplastic transfor-
mation; several types of nevi carry BRAF muta-
tions.
Gene Amplification
An example of gene amplification, which usually 
occurs during tumor progression, is the amplifi-
cation of the dihydrofolate reductase gene (DHFR) 
in methotrexate-resistant acute lymphoblastic leu-
kemia.47 Amplification of DHFR is accompanied 
by cytogenetic alterations that mirror amplifica-
tion of oncogenes.48,49 The amplified DNA seg-
ment usually involves several hundred kilobases 
and can contain many genes. Members of four 
different oncogene families are often amplified: 
MYC, cyclin D1 (or CCND1), EGFR, and RAS. 
MYC is amplified in small-cell lung cancer, breast 
cancer, esophageal cancer, cervical cancer, ovar-
ian cancer, and head and neck cancer, whereas 
amplification of NMYC correlates with an advanced 
tumor stage.50 The t(11;14) translocation juxta-
poses CCND1 and immunoglobulin enhancer ele-
ments and is characteristic of mantle-cell lym-
phoma.14 CCND1 amplification also occurs in 
breast, esophageal, hepatocellular, and head and 
neck cancer. EGFR (ERBB1) is amplified in glio-
blastoma and head and neck cancer. Amplifica-
tion of ERBB2 (also called HER2/neu) in breast 
cancer  correlates  with  a  poor  prognosis.51  A 
monoclonal antibody against the product of this 
oncogene (trastuzumab) is effective in breast can-
cers that overexpress HER2/neu. Table 3 in the 
Supplementary Appendix lists oncogenes that are 
amplified in different types of cancer.
Oncogenes in Cancer Initiation  
and Progression
When chronic myelogenous leukemia converts to 
acute leukemia, the malignant clone acquires an 
additional t(9;22) translocation, an isochromo-
some 17, or trisomy of chromosome 8. When fol-
licular lymphoma becomes aggressive, the lym-
phoma cells often bear a t(8;14) translocation in 
addition to the original t(14;18) translocation. 
These findings support the hypothesis that most 
hematopoietic tumors and soft-tissue sarcomas 
are initiated by the activation of an oncogene, 
followed by alterations in tumor-suppressor genes 
and other oncogenes. In contrast, most carcino-
mas are initiated by the loss of function of a tumor-
suppressor gene, followed by alterations in onco-
genes and additional tumor-suppressor genes.52,53 
This multistep process in human cancer has also 
been found in mouse models carrying activated 
oncogenes or inactivated tumor-suppressor genes, 
in which the duration and aggressiveness of the 
disease can be changed by introducing into the 
mouse genome the same sequential genetic altera-
tions observed in human tumors. Methylation of 
CpG islands located in the promoter regions of a 
number of tumor-suppressor genes has also been 
considered an important epigenetic step in the 
process of carcinogenesis. This topic will be cov-
ered later in this series.
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Oncogenes as Therapeutic Targets
Oncogenic proteins in cancer cells can be target-
ed by small molecules and, when the oncogenic 
protein is expressed on the cell surface, by mono-
clonal antibodies. Table 1 contains a summary of 
the targets and drugs (small molecules and mono-
clonal antibodies) being used in the treatment of 
a variety of human cancers.
Imatinib targets the initial step of the multi-
step process in chronic myelogenous leukemia.54 
The same drug can affect the KIT and PDGFR 
receptor kinases.55,56 Of particular interest are 
inhibitors of the BCL2 family, which can induce 
the  apoptotic  death  of  cancer  cells.  In  acute 
promyelocytic leukemia, which is initiated by a 
t(15;17) chromosome translocation that fuses the 
PML gene to RAR  (a nuclear receptor for retinoic 
acids57-59; see Table 2 in the Supplementary Ap-
pendix), retinoic acid can induce terminal differ-
entiation and death of APL cells. This modality 
is called differentiation therapy.
MicroRNA Genes
MicroRNA genes, unlike other genes involved in 
cancer, do not encode proteins. Instead, the prod-
ucts of these genes consist of a single RNA strand 
of about 21 to 23 nucleotides; their function is to 
regulate gene expression. A microRNA molecule 
can anneal to a messenger RNA (mRNA) con-
taining a nucleotide sequence that complements 
the sequence of the microRNA (Fig. 5). In this 
way, the microRNA blocks protein translation or 
causes degradation of the mRNA. Examples of the 
role microRNA plays in cancer pathophysiology 
involve miR-15a and miR-16-1, which are deleted or 
down-regulated in most indolent cases of chron-
ic lymphocytic leukemia, suggesting an early event 
in the pathogenesis of this disease.59
Mapping of numerous microRNA genes has 
shown that many occur in chromosomal regions 
that undergo rearrangements, deletions, and am-
plifications in cancer cells.60 The regions of the 
genome that are consistently involved in chromo-
somal rearrangements in cancer cells but that 
lack oncogenes or tumor-suppressor genes appear 
to harbor microRNA genes.
Expression profiling of microRNA genes has 
revealed signatures associated with tumor classi-
fication, diagnosis, staging, and progression, as 
well as prognosis and response to treatment.61-63 
For example, microRNA expression profiling can 
distinguish between indolent and aggressive forms 
of chronic lymphocytic leukemia,62 and expres-
sion of a small panel of microRNA genes corre-
lates with prognosis in stage 1 lung cancer.63 
Some microRNA genes that are deregulated in 
chronic lymphocytic leukemia have germ-line or 
somatic mutations in a microRNA precursor that 
affect  the  processing  of  short  single-stranded 
microRNA molecules.62 MicroRNA genes can be 
up-regulated or down-regulated in cancer cells.64 
The up-regulated genes function as oncogenes by 
down-regulating tumor-suppressor genes, where-
as the down-regulated genes function as tumor-
Table 1. Cancer Therapies That Target Oncogenic Proteins.*
Anticancer Drug Target Disease
Monoclonal antibodies
Trastuzumab (Herceptin, Genentech) ERBB2 Breast cancer
Cetuximab (Erbitux, ImClone) EGFR Colorectal cancer
Bevacizumab (Avastin, Genentech) VEGF Colorectal cancer, non–small-cell lung cancer
Small molecules
Imatinib (Gleevec, Novartis) ABL, PDGFR, KIT Chronic myelogenous leukemia, gastrointes-
tinal stromal tumors, chordoma
Gefitinib (Iressa, AstraZeneca) EGFR Non–small-cell lung cancer
Erlotinib (Tarceva, Genentech) EGFR Non–small-cell lung cancer
Sorafenib (Nexavar, Bayer/Onyx) VEGFR, PDGFR, FLT3 Renal-cell carcinoma
Sunitinib (Sutent, Pfizer) VEGFR, PDGFR, FLT3 Gastrointestinal stromal tumors, renal-cell 
carcinoma
* EGFR denotes epidermal growth factor receptor, FLT3 FMS-like tyrosine kinase 3, PDGFR platelet-derived growth factor 
receptor, and VEGF vascular endothelial growth factor.
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suppressor genes by down-regulating oncogenes. 
The function of microRNA genes depends on 
their targets in a specific tissue. A microRNA 
gene can be a tumor suppressor if in a given cell 
type its critical target is an oncogene, and it can 
be an oncogene if in a different cell type its target 
is a tumor-suppressor gene.
Up-regulation of microRNA genes can be due 
to amplification, deregulation of a transcription 
factor, or demethylation of CpG islands in the 
promoter regions of the gene. For example, the 
ALL1 (MLL) fusion proteins of acute lymphoblas-
tic leukemia or acute myeloblastic leukemia car-
rying chromosome 11q23 translocations target the 
Drosha nuclease complex to specific microRNA 
genes, including miR191, thereby enhancing the 
processing of their microRNA precursors.65 The 
miR191 gene is also up-regulated in numerous 
types of solid cancers,64 suggesting that it is the 
downstream target of signal-translocation path-
ways involved in cancer.65 MicroRNA genes func-
tioning as tumor suppressors can be down-regu-
lated because of deletions, epigenetic silencing, or 
loss of the expression of one or more transcrip-
tion factors.
The miR155 gene is overexpressed in diffuse 
large B-cell lymphoma,66 the aggressive form of 
chronic lymphocytic leukemia,62 and in breast, 
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MicroRNA (miRNA) is transcribed mostly by RNA polymerase (pol) II and less frequently by RNA pol III. The primary transcript (pri-
  microRNA) can be quite large. During the process of splicing, pri-microRNA is processed in the nucleus by an enzymatic complex that 
includes Drosha and DGCR8, which leads to the formation of a smaller (70-to-100 nucleotide), second hairpin precursor named pre-
  microRNA. This second precursor binds exportin-5 in the nucleus and is transported to the cytoplasm, where it is cleaved by Dicer into 
mature microRNA. This mature microRNA, for the most part, binds to the 3' untranslated region of messenger RNA (mRNA) and, de-
pending on the degree of complementarity with the target RNA, can lead to the degradation or blockage of translation mRNA. Recent 
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lung, and colon cancers. In transgenic mice carry-
ing this gene under control of the Eµ enhancer 
of immunoglobulin genes,67 overexpression of 
miR155 causes acute lymphoblastic leukemia or 
high-grade lymphoma, indicating that deregula-
tion of a single microRNA gene can cause malig-
nant  transformation.67  Since  it  takes  several 
months for the tumors in these mice to become 
aggressive, it is likely that additional genetic alter-
ations are needed for the development of frank 
neoplasia.
Members  of  the  LET7  microRNA  family, 
which are deleted or underexpressed in lung can-
cer, target RAS68; loss of LET7 results in over-
expression of RAS.68 MiR15a and miR-16-1, the 
microRNAs that are deleted or down-regulated 
in chronic lymphocytic leukemia, cause over-
expression of BCL2, which protects cells from 
apoptosis (Fig. 4).69 The expression of a set of 
21 microRNAs is altered in at least three types 
of solid tumors.64 One of these 21 genes, miR21, 
is of particular interest because it inhibits ex-
pression of the tumor suppressor PTEN.70 PTEN 
encodes a phosphatase involved in the PI3K ki-
nase signaling pathway and is deleted, mutated, 
or silenced in advanced breast, lung, gastric, and 
prostate cancers.70
Summary
The identification of oncogenes involved in the 
initiation and progression of tumors has gener-
ated targets for the development of new antican-
cer drugs. Several new drugs, small molecules, 
and monoclonal antibodies directly affecting on-
cogene products have been developed, and more 
will follow. Considerable progress has been made 
in producing small molecules capable of inhibit-
ing the enzymatic activity of ABL, KIT, EGFR, and 
ERBB2. For cases in which the oncogene prod-
ucts are not enzymes, it has been much more dif-
ficult to develop new agents.
The advantage of targeted therapy is the de-
pendency of cancer cells on the oncogene prod-
uct for growth and survival. Thus, cancer cells are 
more sensitive to the treatment than are normal 
cells. All targets, however, are not equivalent. It is 
possible to foresee the development of multiple 
drugs that have multiple targets involved in the 
development of cancer. The discovery of the in-
volvement of microRNAs in the initiation and 
progression of human cancer may provide addi-
tional targets for anticancer treatments.
No potential conflict of interest relevant to this article was 
reported.
References
Groffen  J,  Stephenson  JR,  Heister-
kamp N, et al. Philadelphia chromosomal 
breakpoints are clustered within a limited 
region, bcr, on chromosome 22. Cell 1984; 
36:93-4.
Shtivelman E, Lifshitz B, Gale RP, Ca-
naani E. Fused transcript of abl and bcr 
genes in chronic myelogenous leukemia. 
Nature 1985;315:550-4.
Druker BJ, Talpaz M, Resta DJ, et al. 
Efficacy and safety of a specific inhibitor 
of the BCR-ABL tyrosine kinase in chronic 
myeloid leukemia. N Engl J Med 2001;344: 
1031-7.
Ottmann OG, Druker BJ, Sawyers CL, 
et al. A phase 2 study of imatinib in pa-
tients with relapsed or refractory Philadel-
phia chromosome-positive acute lymphoid 
leukemias. Blood 2002;100:1965-71.
Roche-Lestienne C, Soenen-Cornu V, 
Grardel-Duflos N, et al. Several types of 
mutations of the Abl gene can be found in 
chronic myeloid leukemia patients resis-
tant to STI571, and they can pre-exist to 
the onset of treatment. Blood 2002;100: 
1014-8.
Croce CM, Shander M, Martinis J, et al. 
Chromosomal location of the genes for 
human immunoglobulin heavy chain. Proc 
Natl Acad Sci U S A 1979;76:3416-9.
Erikson J, Martinis J, Croce CM. As-
1.
2.
3.
4.
5.
6.
7.
signment of the genes for human lambda 
immunoglobulin chains to chromosome 
22. Nature 1981;294:173-5.
Dalla Favera R, Bregni M, Erikson J, 
Patterson D, Gallo RC, Croce CM. Human 
c-myc onc gene is located on the region of 
chromosome  8  that  is  translocated  in 
Burkitt lymphoma cells. Proc Natl Acad 
Sci U S A 1982;79:7824-7.
Croce CM, Thierfelder W, Erikson J, et 
al. Transcriptional activation of an unre-
arranged and untranslocated c-myc onco-
gene by translocation of a C lambda locus 
in Burkitt lymphoma. Proc Natl Acad Sci 
U S A 1983;80:6922-6.
Erikson J, Nishikura K, ar-Rushdi A, 
et al. Translocation of an immunoglobu-
lin kappa locus to a region 3  of an unre-
arranged c-myc oncogene enhances c-myc 
transcription. Proc Natl Acad Sci U S A 
1983;80:7581-5.
ar-Rushdi A, Nishikura K, Erikson J, 
Watt R, Rovera G, Croce CM. Differential 
expression of the translocated and the un-
translocated  c-myc  oncogene  in  Burkitt 
lymphoma. Science 1983;222:390-3.
Capon DJ, Chen EY, Levinson AD, See-
burg PH, Goeddel DV. Complete nucleo-
tide sequences of the T24 human bladder 
carcinoma oncogene and its normal ho-
mologue. Nature 1983;302:33-7.
8.
9.
10.
11.
12.
McCoy MS, Toole JJ, Cunningham JM, 
Chang EH, Lowy DR, Weinberg RA. Char-
acterization of a human colon/lung carci-
noma oncogene. Nature 1983;302:79-81.
Tsujimoto Y, Yunis J, Onorato-Showe 
L, Nowell PC, Croce CM. Molecular clon-
ing  of  the  chromosomal  breakpoint  of   
B cell lymphomas and leukemias with the 
t(11;14) chromosome translocation. Sci-
ence 1984;224:1403-6.
Tsujimoto Y, Cossman J, Jaffe E, Croce 
CM. Involvement of the bcl-2 gene in hu-
man follicular lymphoma. Science 1985; 
228:1440-3.
Adams JM, Harris AW, Pinkert CA, et 
al. The c-myc oncogene driven by immu-
noglobulin enhancers induces lymphoid 
malignancy  in  transgenic  mice.  Nature 
1985;318:533-8.
Leder A, Pattengale PK, Kuo A, Stew-
art TA, Leder P. Consequences of wide-
spread deregulation of the c-myc gene in 
transgenic mice: multiple neoplasms and 
normal development. Cell 1986;45:485-95.
Konopka JB, Watanabe SM, Singer JW, 
Collins SJ, Witte ON. Cell lines and clini-
cal  isolates  derived  from  Ph1-positive 
chronic  myelogenous  leukemia  patients 
express  c-abl  proteins  with  a  common 
structural alteration. Proc Natl Acad Sci   
U S A 1985;82:1810-4.
13.
14.
15.
16.
17.
18.
Copyright © 2008 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at INSERM DISC DOC on October 8, 2009 . molecular origins of cancer
n engl j med 358;5  www.nejm.org  january 31, 2008 511
Tsujimoto Y, Gorham J, Cossman J, 
Jaffe E, Croce CM. The t(14;18) chromo-
some translocations involved in B-cell neo-
plasms result from mistakes in VDJ join-
ing. Science 1985;229:1390-3.
Finger LR, Harvey RC, Moore RCA, 
Showe LC, Croce CM. A common mecha-
nism of chromosomal translocation in 
T- and B-cell neoplasia. Science 1986;234: 
982-5.
Shaulian E, Karin M. AP-1 in cell pro-
liferation and survival. Oncogene 2001;20: 
2390-400.
Idem. AP-1 as a regulator of cell life and 
death. Nat Cell Biol 2002;4(5):E131-E136.
Croce CM. Role of chromosome trans-
locations in human neoplasia. Cell 1987; 
49:155-6.
Tomlins SA, Rhodes DR, Perner S, et 
al. Recurrent fusion of TMPRSS2 and ETS 
transcription factor genes in prostate can-
cer. Science 2005;310:644-8.
Peterson CL, Workman JL. Promoter 
targeting and chromatin remodeling by 
the SWI/SNF complex. Curr Opin Genet 
Dev 2000;10:187-92.
Jenuwein T, Allis CD. Translating the 
histone code. Science 2001;293:1074-80.
Strahl BD, Allis CD. The language of 
covalent  histone  modifications.  Nature 
2000;403:41-5.
Nakamura T, Mori T, Tada S, et al. 
ALL-1 is a histone methyltransferase that 
assembles a supercomplex of proteins in-
volved in transcriptional regulation. Mol 
Cell 2002;10:1119-28.
Heldin  CH,  Westermark  B.  Mecha-
nism of action and in vivo role of platelet-
derived growth factor. Physiol Rev 1999;79: 
1283-316.
Giles RH, van Es JH, Clevers H. Caught 
up in a Wnt storm: Wnt signaling in can-
cer. Biochim Biophys Acta 2003;1653:1-24.
Heldin CH. Dimerization of cell sur-
face receptors in signal transduction. Cell 
1995;80:213-23.
Arteaga CL. Epidermal growth factor 
receptor dependence in human tumors: 
more  than  just  expression?  Oncologist 
2002;7:Suppl 4:31-9.
Joensuu H, Dimitrijevic S. Tyrosine 
kinase inhibitor imatinib (STI571) as an 
anticancer agent for solid tumours. Ann 
Med 2001;33:451-5.
Tamborini E, Bonadiman L, Greco A, 
et  al.  A  new  mutation  in  the  KIT  ATP 
pocket causes acquired resistance to ima-
tinib in a gastrointestinal stromal tumor 
patient. Gastroenterology 2004;127:294-9.
Pawson T, Warner N. Oncogenic re-
wiring  of  cellular  signaling  pathways. 
Oncogene 2007;26:1268-75.
Sicheri F, Moarefi I, Kuriyan J. Crystal 
structure of the Src family tyrosine kinase 
Hck. Nature 1997;385:602-9.
Kaziro Y, Itoh H, Kozasa T, Nakafuku 
M, Satoh T. Structure and function of sig-
nal-transducing  GTP-binding  proteins. 
Annu Rev Biochem 1991;60:349-400.
Salgia R, Skarin AT. Molecular abnor-
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
malities in lung cancer. J Clin Oncol 1998; 
16:1207-17.
Tsujimoto Y, Croce CM. Analysis of the 
structure, transcripts, and protein prod-
ucts of  bcl-2, the gene involved in human 
follicular lymphoma. Proc Natl Acad Sci 
U S A 1986;83:5214-8.
Tsujimoto  Y,  Ikegaki  N,  Croce  CM. 
Characterization of the protein product of 
bcl-2, the gene involved in human follicu-
lar lymphoma. Oncogene 1987;2:3-7.
Adams JM, Cory S. The Bcl-2 apop-
totic switch in cancer development and 
therapy. Oncogene 2007;26:1324-37.
Bishop JM. Molecular themes in onco-
genesis. Cell 1991;44:235-48.
Rodenhuis S. ras And human tumors. 
Semin Cancer Biol 1992;3:241-7.
Beaupre  DM,  Kurzrock  R.  RAS  and 
leukemia: from basic mechanisms to gene-
directed therapy. J Clin Oncol 1999;17: 
1071-9.
Davies H, Bignell GR, Cox C, et al. 
Mutations of the BRAF gene in human 
cancer. Nature 2002;417:949-54.
Frattini M, Ferrario C, Bressan P, et al. 
Alternative mutations of BRAF, RET and 
NTRK1 are associated with similar but 
distinct gene expression patterns in pap-
illary thyroid cancer. Oncogene 2004;23: 
7436-40.
Alt  FW,  Kellems  RE,  Bertino  JR, 
Schimke  RT.  Selective  multiplication  of 
dihydrofolate reductase genes in metho-
trexate-resistant variants of cultured mu-
rine cells. J Biol Chem 1978;253:1357-70.
Cowell JK. Double minutes and homo-
geneously staining regions: gene amplifi-
cation  in  mammalian  cells.  Annu  Rev 
Genet 1982;16:21-59.
King CR, Kraus MH, Aaronson SA. 
Amplification  of  a  novel  v-erbB-related 
gene in a human mammary carcinoma. 
Science 1985;229:974-6.
Schwab  M,  Alitalo  K,  Klempnauer 
KH, et al. Amplified DNA with limited 
homology  to  myc  cellular  oncogene  is 
shared by human neuroblastoma cell lines 
and a neuroblastoma tumour. Nature 1983; 
305:245-8.
Press MF, Bernstein L, Thomas PA, et 
al. HER-2/neu gene amplification charac-
terized by fluorescence in situ hybridiza-
tion:  poor  prognosis  in  node-negative 
breast carcinomas. J Clin Oncol 1997;15: 
2894-904.
Ohta M, Inoue H, Cotticelli MG, et al. 
The  human  FHIT  gene,  spanning  the 
chromosome 3p14.2 fragile site and renal 
carcinoma associated translocation break-
point, is abnormal in digestive tract can-
cers. Cell 1996;84:587-97.
Huebner  K,  Croce  CM.  FRA3B  and 
other common fragile sites: the weakest 
links. Nat Rev Cancer 2001;1:214-21.
Goldman JM, Melo JV. Targeting the 
BCR-ABL tyrosine kinase in chronic mye-
loid leukemia. N Engl J Med 2001;344: 
1084-6.
Heinrich MC, Blanke CD, Druker BJ, 
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
Corless CL. Inhibition of KIT tyrosine ki-
nase activity: a novel molecular approach 
to the treatment of KIT-positive malig-
nancies. J Clin Oncol 2002;20:1692-703.
Casali PG, Messina A, Stacchiotti S, et 
al. Imatinib mesylate in chordoma. Cancer 
2004;101:2086-97.
Wang ZG, Delva L, Gaboli M, et al. Role 
of PML in cell growth and the retinoic 
acid pathway. Science 1998;279:1547-51.
Salomoni P, Pandolfi PP. The role of 
PML in tumor suppression. Cell 2002;108: 
165-70.
Calin GA, Dumitru CD, Shimizu M, et 
al. Frequent deletions and down regula-
tion  of  micro-RNA  genes  miR15  and 
miR16 at 13q14 in chronic lymphocytic 
leukemia. Proc Natl Acad Sci U S A 2002; 
99:15524-9.
Calin GA, Sevignani C, Dumitru CD, 
et al. Human microRNA genes are fre-
quently  located  at  fragile  sites  and  ge-
nomic regions involved in cancers. Proc 
Natl Acad Sci U S A 2004;101:2999-3004.
Calin GA, Croce CM. MicroRNA signa-
tures in human cancers. Nat Rev Cancer 
2006;6:857-66.
Calin GA, Ferracin M, Cimmino A, et 
al. A microRNA signature associated with 
prognosis and progression in chronic lym-
phocytic leukemia. N Engl J Med 2005; 
353:1793-801. [Erratum, N Engl J Med 
2006;355:533.]
Yanaihara N, Caplen N, Bowman E, et 
al. Unique microRNA molecular profiles 
in lung cancer diagnosis and prognosis. 
Cancer Cell 2006;9:189-98.
Volinia S, Calin GA, Liu C-G, et al.   
A microRNA expression signature of hu-
man solid tumors defines cancer gene tar-
gets. Proc Natl Acad Sci U S A 2006;103: 
2257-61.
Nakamura T, Canaani E, Croce CM. 
Oncogenic  All1  fusion  proteins  target 
Drosha-mediated microRNA processing. 
Proc  Natl  Acad  Sci  U  S  A  2007;104: 
10980-5.
Eis PS, Tam W, Sun L, et al. Accumu-
lation of miR-155 and BIC RNA in human 
B cell lymphomas. Proc Natl Acad Sci U S A 
2005;102:3627-32.
Costinean S, Zanesi N, Pekarsky Y, et 
al. Pre-B cell proliferation and lympho-
blastic leukemia/high grade lymphoma in 
E(mu)-miR155 transgenic mice. Proc Natl 
Acad Sci U S A 2006;103:7024-9.
Johnson SM, Grosshans H, Shingara J, 
et al. RAS is regulated by the let-7 micro-
RNA family. Cell 2005;120:635-47.
Cimmino A, Calin GA, Fabbri M, et al. 
miR-15 And miR-16 induce apoptosis by 
targeting BCL2. Proc Natl Acad Sci U S A 
2005;102:13944-9.  [Erratum,  Proc  Natl 
Acad Sci U S A 2006;103:2464.]
Meng F, Henson R, Lang M, et al. In-
volvement of human microRNA in growth 
and response to chemotherapy in human 
cholangiocarcinoma cell lines. Gastroen-
terology 2006;130:2113-29.
Copyright © 2008 Massachusetts Medical Society.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
Copyright © 2008 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at INSERM DISC DOC on October 8, 2009 . 